tiprankstipranks
Advertisement
Advertisement

INCY Stock Latest News

Incyte price target raised to $95 from $92 at RBC Capital
The FlyIncyte price target raised to $95 from $92 at RBC Capital
2h ago
INCY
Incyte Announces Upcoming Resignation of Board Member Schaffert
PremiumCompany Announcements
Incyte Announces Upcoming Resignation of Board Member Schaffert
8d ago
8K
INCY
Incyte announces new 54-week data on safety, efficacy of povorcitinib
PremiumThe Fly
Incyte announces new 54-week data on safety, efficacy of povorcitinib
9d ago
INCY
Incyte Announces Major Executive Leadership and Commercial Reorganization
PremiumCompany Announcements
Incyte Announces Major Executive Leadership and Commercial Reorganization
12d ago
8K
INCY
Incyte price target lowered to $94 from $104 at UBS
PremiumThe Fly
Incyte price target lowered to $94 from $104 at UBS
13d ago
INCY
Incyte appoints Stein as Chief Medical Officer, Issa as EVP
PremiumThe FlyIncyte appoints Stein as Chief Medical Officer, Issa as EVP
13d ago
INCY
Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial
Premium
Company Announcements
Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial
19d ago
INCY
Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
Premium
The Fly
Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
21d ago
INCY
Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
22d ago
ECL
ETN
Incyte downgraded to Hold from Buy at Jefferies
PremiumThe Fly
Incyte downgraded to Hold from Buy at Jefferies
22d ago
INCY
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing
PremiumCompany Announcements
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing
27d ago
INCY
Incyte’s Ruxolitinib Pediatric Leukemia Study Update: What Investors Should Watch
PremiumCompany Announcements
Incyte’s Ruxolitinib Pediatric Leukemia Study Update: What Investors Should Watch
27d ago
INCY
Balancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte
PremiumRatingsBalancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte
1M ago
INCY
Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion
Premium
Company Announcements
Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion
1M ago
8K
INCY
Incyte announces European Commission approval of Zynyz
Premium
The Fly
Incyte announces European Commission approval of Zynyz
1M ago
INCY
Eli Lilly, Incyte: EMA’s CHMP issues positive opinion for Olumiant
PremiumThe Fly
Eli Lilly, Incyte: EMA’s CHMP issues positive opinion for Olumiant
1M ago
LLY
INCY
Knight Therapeutics announces NIKTIMVO regulatory submission in Brazil
PremiumThe Fly
Knight Therapeutics announces NIKTIMVO regulatory submission in Brazil
2M ago
INCY
Incyte price target raised to $117 from $116 at Barclays
PremiumThe Fly
Incyte price target raised to $117 from $116 at Barclays
2M ago
INCY
Incyte’s Profit Outlook Threatened by Emerging U.S. ‘Most Favored Nation’ Drug Pricing Policies
PremiumCompany Announcements
Incyte’s Profit Outlook Threatened by Emerging U.S. ‘Most Favored Nation’ Drug Pricing Policies
2M ago
INCY
Incyte price target raised to $102 from $94 at Morgan Stanley
PremiumThe FlyIncyte price target raised to $102 from $94 at Morgan Stanley
2M ago
INCY
Incyte price target raised to $120 from $119 at Stifel
Premium
The Fly
Incyte price target raised to $120 from $119 at Stifel
2M ago
INCY
Incyte: Long-Term Revenue Durability and Underappreciated Pipeline Support Buy Rating and $135 Target
Premium
Ratings
Incyte: Long-Term Revenue Durability and Underappreciated Pipeline Support Buy Rating and $135 Target
2M ago
INCY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >